An observational study in Prostatic Neoplasms, Castration-Resistant, sponsored by Novartis Pharmaceuticals. Recruiting at 1 site in United States. Open to male participants aged 18 Years to 115 Years. Per ClinicalTrials.gov, last updated 2026-10-15.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 51 studies in Prostatic Neoplasms, Castration-Resistant with a site in United States — 18 open to participants now, 24 under way, 3 of them phase 3. Prostatic Neoplasms, Castration-Resistant · United States.
Among the 51 studies in Prostatic Neoplasms, Castration-Resistant with a site in United States, this one is one of 6 that started in 2026, is one of 6 observational ones, reaches primary completion later than 6 of the 23 other live ones, and was the 48th registered.
86 studies on the registry are indexed under Prostatic Neoplasms, Castration-Resistant; 29 are open to participants now.
Browse Prostatic Neoplasms, Castration-Resistant studies →18 of the 51 studies in Prostatic Neoplasms, Castration-Resistant with a site in United States are open now. Recruiting first, the newest first:
Coherus Oncology, Inc. · Sites in United States
Ages 18+ · Men only
Novartis Pharmaceuticals · Sites in United States
Ages 18–100 · Men only
Flare Therapeutics Inc. · Sites in United States
Ages 18+ · Men only
Novartis Pharmaceuticals · Sites in United States
Ages 18–115 · Men only
T.O.A.D. Oncology SA · Sites in United States, Australia, Canada and 2 more countries
Ages 18+ · Men only
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 26 Prostatic Neoplasms, Castration-Resistant studies recruiting now, 22 (85%) set no upper age limit and none (0%) stop at 75 or younger; 1 takes children under 18; none take healthy volunteers.
This study: 18 Years to 115 Years · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
51 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 24 · Phase 2 21 · Phase 3 8 · Phase 4 2
First in 2014; this study’s year is marked. 6 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 17,111 is above the median of 432 across 16 observational studies indexed under Prostatic Neoplasms, Castration-Resistant.
Median enrollment 82 across the 43 interventional studies, 1,908 across the 6 observational. Of the 23 that completed or were terminated, 11 (48%) have results posted.
This tab as a report to print or save as PDF → With an account.
42 of 51 have an industry lead sponsor. The 10 most frequent:
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,723 studies on the registry; 222 are open to participants now.
Of its 587 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
Novartis has 7 studies filed under Prostatic Neoplasms, Castration-Resistant — fewer than ten, so there is no comparison to draw.
8 of the studies in Prostatic Neoplasms, Castration-Resistant with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07225946Phase 3Janssen Research & Development, LLCA Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer | 2027-11-19 |
| NCT07697989Novartis PharmaceuticalsPluvicto Real-world Investigation in Survival in Metastatic CRPC | 2027-01-31 |
| NCT07677254Novartis PharmaceuticalsA Study of Real-World Characteristics, Treatment Patterns, and Clinical Outcomes in Patients With Metastatic Castration-Resistant Prostate Cancer | 2027-05-31 |
| NCT07677267Novartis PharmaceuticalsA Study of Real-World Characteristics, Treatment Patterns, and Outcomes Among mCRPC Patients Previously Treated With an Androgen Receptor Pathway Inhibitor, Taxane-Based Chemotherapy, and Lutetium-177 Vipivotide Tetraxetan | 2027-05-31 |
| NCT05519449Janux TherapeuticsStudy of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01) | 2027-07 |
Add all 8 to your calendar (.ics) → With an account.
Among the 51 studies in Prostatic Neoplasms, Castration-Resistant with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The aim of this study is to assess treatment patterns, clinical outcomes, and patient characteristics among adults with metastatic castration-resistant prostate cancer (mCRPC) in the United States (US) real-world clinical practice. This study will be conducted using data extracted from the PRECISION (PRostatE Cancer dISease observatION) data platform.
Adult male patients with a confirmed mCRPC diagnosis in the US in the last 5 years who are included in the PRECISION data platform.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria:
Adult male patients with a recent diagnosis of mCRPC in PRECISION.
Number of Patients by Prior Therapies
Time frame: Baseline
Number of Patients by Number of Post-index Lines of Therapy (LOTs)
Time frame: Up to approximately 5 years
Number of Patients by Type of Therapy at Each LOT
Time frame: Up to approximately 5 years
Percentage of Patients Switching From One Type of Therapy to Another at Each LOT
Time frame: Up to approximately 5 years
Time to First-line (1L) Treatment Initiation (TTTI)
Time from index date (mCRPC diagnosis) to the start of 1L treatment.
Time frame: Up to approximately 5 years
Time to Next Therapy (TTNT) for Each LOT
Time from the end of each LOT to initiation of the next LOT.
Time frame: Up to approximately 5 years
Number of Patients by Patient Characteristics
Patient characteristics include race, geographical region, insurance status, marital status, type of treatment center, comorbidities, Gleason score, disease stage at diagnosis, and prostate-specific antigen (PSA) level.
Time frame: Baseline
Age
Time frame: Baseline
Progression-free Survival (PFS) From Index Date
PFS from index date: time from mCRPC diagnosis (index date) until progression or death from any cause.
Time frame: Up to approximately 5 years
PFS From Each LOT
PFS from each LOT, among those with that LOT: time from the date of initiation of the LOT until progression or death from any cause.
Time frame: Up to approximately 5 years
Overall Survival (OS) From Index Date
OS from index date: time from mCRPC diagnosis (index date) until death from any cause.
Time frame: Up to approximately 5 years
OS From Each LOT
OS from each LOT, among those with that LOT: time from the date of initiation of the LOT until death from any cause.
Time frame: Up to approximately 5 years
Plan to share: No
No publications or documents are linked to this record.
Started Jun 2026 (actual). Primary completion is estimated for May 2027, 11 months after the start.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 15, 2026: primary completion Nov 2026 → May 2027 and completion Nov 2026 → May 2027.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Prostatic Neoplasms, Castration-Resistant →